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Introduction {#sec1}
============

Male and female mammals carry the same complement of autosomes but differ with respect to their sex chromosomes: females have two X chromosomes (XX) while males have one X chromosome and one Y chromosome (XY). The X and Y chromosomes evolved from a pair of ancestral autosomes following the acquisition of the male-determining locus *Sry* on the proto-Y chromosome. The subsequent appearance of sexually antagonistic alleles near *Sry* caused progressive suppression of X-Y recombination ([@bib4], [@bib18], [@bib39], [@bib58]). The X chromosome managed to retain most of its ancestral genes through ongoing X-X recombination in the female germline. In contrast, without a partner with which to recombine, the Y chromosome lost most of its original gene content through genetic drift ([@bib12], [@bib13]).

Evolutionary loss of genes from the Y chromosome led to a disparity in the dosage of X chromosome versus autosomal genes, with males becoming monosomic for X-linked gene products. Susumo Ohno proposed that to rectify this imbalance, expression of X chromosome genes was increased 2-fold to match the output of the diploid autosomal complement, i.e., giving an X-to-autosome ratio (X:A) of 1 (termed Ohno\'s hypothesis) ([@bib61]). This process, X chromosome upregulation, was also acquired in females, leading to a 2-fold excess in X gene expression compared with males. To equalize this resulting sex difference in X gene output, mammals subsequently evolved X chromosome inactivation, the global silencing of one of the two X chromosomes in females ([@bib25], [@bib31]). Together, X upregulation and X inactivation ensure equalization of gene dosage both within, and between, the sexes.

Consistent with Ohno\'s hypothesis, X upregulation has been observed in multiple organisms including *Drosophila melanogaster* ([@bib17], [@bib30], [@bib70]), *Caenorhabditis elegans* ([@bib34]), and mammals ([@bib1], [@bib34], [@bib49], [@bib60]). More recently, RNA-sequencing (RNA-seq) analyses showed that the X:A ratio in males and females is nearer 0.5, and therefore that X upregulation does not occur ([@bib43], [@bib82]). The discrepancy between these studies has been attributed to the choice of genes used to assay X upregulation. The X chromosome is enriched in tissue-specific genes, including those expressed in the testis and ovary ([@bib24], [@bib45], [@bib56], [@bib57]). These genes are silent in the soma, and thus their inclusion can artificially lower estimations of the somatic X:A ratio ([@bib22]). A reappraisal of X:A ratios using expression thresholds that exclude such genes has confirmed the existence of X upregulation ([@bib22], [@bib50], [@bib84]), and mechanistic studies have identified transcriptional and post-transcriptional mechanisms by which upregulation is achieved ([@bib23], [@bib28], [@bib84], [@bib85]). X upregulation preferentially affects a subset of expressed X genes with dosage-sensitive housekeeping functions ([@bib5], [@bib62], [@bib63]).

To date, studies of X upregulation have focused on somatic tissues, and it is therefore unclear whether germ cells also conform to Ohno\'s hypothesis. In mice, primordial germ cells (PGCs) arise from the post-implantation epiblast and migrate along the hindgut endoderm before colonizing the gonad. During this time, they undergo genome-wide reprogramming in which the pluripotency gene network is reactivated, somatic genes are repressed, and genomic imprints are removed ([@bib32], [@bib33], [@bib48], [@bib69], [@bib72]). In females, one of the two X chromosomes is already inactive prior to PGC specification ([@bib37], [@bib54], [@bib71]). During germline reprogramming, the inactive X chromosome is subsequently reactivated ([@bib14], [@bib21], [@bib71]). However, expression from the active X chromosome during and after reprogramming has not been examined, and therefore the status of X dosage compensation throughout male and female germline development is unclear.

To address this point, we have generated extensive RNA-seq datasets from wild-type XY male and XX female, as well as sex chromosomally abnormal XO female (Turner syndrome) and XX male (Klinefelter syndrome variant) mouse germ cells before, during, and after reprogramming. Consistent with Ohno\'s hypothesis, early male and female germ cells exhibit upregulation of the active X chromosome. Later, however, they display unusual and sexually dimorphic dosage compensation patterns. Female germ cells exhibit a phase of X dosage excess, during which X:A ratios exceed 1, while male germ cells, conversely, exhibit X dosage decompensation, with X:A ratios falling below 1. These X dosage compensation patterns are conserved in human germ cells. Intriguingly, sex chromosome variant mice manifest a "sex-reversed" dosage compensation state: XO female germ cells become dosage decompensated like XY males, while XX male germ cells exhibit X dosage excess like XX females. Our studies reveal important differences in X dosage compensation states between the germline and soma and provide fresh insight into the etiology of subfertility caused by sex chromosome abnormalities.

Results {#sec2}
=======

Creation of Germ Cell and Somatic Cell RNA-Seq Datasets for Analysis of X Dosage Compensation {#sec2.1}
---------------------------------------------------------------------------------------------

For our analysis, we wished to track X dosage compensation states throughout the entirety of embryonic germ cell development ([Figure S1](#mmc1){ref-type="supplementary-material"}). In mice, PGCs arise from the post-implantation epiblast at embryonic day 7.25 (E7.25) ([@bib68]). These PGCs migrate along the hindgut endoderm and colonize the gonad between E10.5 and E11.5 ([@bib68]). Following sex determination at E11.5, germ cells develop in a sexually dimorphic manner. In females, they divide mitotically until E12.5, before entering meiosis. In males, in contrast, germ cells divide mitotically until E16.5, when they undergo quiescence at the G~0~ phase of the cell cycle ([@bib38], [@bib77]). After birth, they resume mitosis and enter meiosis at around postnatal day 10 (P10).

As a baseline reflecting the epigenetic state of PGC and somatic cell precursors, we isolated E6.5 epiblasts ([@bib69]). For later time points, we used mice carrying a previously described *Oct4*-EGFP transgene ([@bib86]). We used fluorescence-activated cell sorting (FACS) to collect highly purified populations of germ cells (EGFP-positive) and gonadal somatic cells (EGFP-negative) from both sexes at E9.5, E11.5, E12.5, E14.5, E15.5, E16.5, and E18.5, as well as purified spermatogonia at P2. For purification of leptotene/zygotene spermatocytes at P11, we used an alternative reporter, ROSA26-Tomato-EGFP ([@bib59]) carrying a *Stra8*-Cre transgene ([@bib67]). Non-gonadal somatic cell control datasets were generated from E14.5 male and female liver and tail. Germ cells from individual embryos were processed to make cDNA libraries and served as biological replicates. We generated 184 libraries for our analysis from a total of 60 separate conditions ([Table S1](#mmc1){ref-type="supplementary-material"}). To assess replicate correlation, we performed t-distributed stochastic neighbor embedding (t-SNE) analysis on our dataset, which revealed a high degree of cross-replicate clustering ([Figure S2](#mmc1){ref-type="supplementary-material"}A). We also computed Spearman correlation coefficients between samples, which were typically higher than 0.8, confirming a high level of replicate correlation ([Figure S2](#mmc1){ref-type="supplementary-material"}B).

Unsupervised hierarchical clustering of RNA-seq profiles revealed that early germ cells, late germ cells, and somatic (gonadal and non-gonadal) cells formed three distinct branches (59 of our 60 conditions), suggesting that our transcriptomic data recapitulated the ontology of germ cell development ([Figure 1](#fig1){ref-type="fig"}A). We further interrogated the data using multi-dimensional scaling (MDS), which once again highlighted the transcriptional distinction between these three groups. The first dimension separated somatic cells from germ cells, and developmental progression was noted along the second dimension, indicating progressive germ cell differentiation after PGC colonization of the gonad ([Figure 1](#fig1){ref-type="fig"}B). The single outlier condition in hierarchical clustering (E12.5 XX male) clearly segregated as germ cells during MDS. We assayed the expression of previously described pluripotency and meiotic genes ([@bib69]) in our germ cell populations. In both male and female germ cells, pluripotency genes were upregulated following the time of PGC specification at E7.25, and were subsequently repressed following sex determination ([Figure 1](#fig1){ref-type="fig"}C). Meiotic genes were upregulated in female germ cells from E12.5 but remained repressed at this time point in males ([Figure 1](#fig1){ref-type="fig"}D). Thus, our germ cell population faithfully recapitulated the orderly program of sex-specific changes that occur during germ cell development.

Upregulation of the Active X Chromosome in Non-gonadal and Gonadal Somatic Cells {#sec2.2}
--------------------------------------------------------------------------------

Next, we ascertained whether X upregulation occurs in somatic cells. We analyzed X chromosome activity in XX and XY non-gonadal somatic cells (E14.5 liver and tail) and gonadal somatic cells (E9.5--E18.5). In both males and females, these cells carry one active X chromosome, as females undergo somatic X chromosome inactivation. In order to assay expression at a chromosome-wide level, we charted median X chromosome expression in relation to that of median expression from the autosomes as a comparison. This X:A ratio was calculated as the ratio of the respective medians, with 95% confidence intervals of the ratio computed using the bootstrap method, which involves random sampling from a distribution with replacement ([@bib26]).

Consistent with earlier studies ([@bib43], [@bib82]), when all genes with a fragments per kilobase of transcript per million reads (FPKM) ≥0 were included in our analysis, X:A ratios were low in non-gonadal and gonadal somatic tissues, implying that X upregulation does not occur ([Figure 2](#fig2){ref-type="fig"}A). However, the X chromosome is enriched relative to the autosomes in genes that are silent in somatic cells, and therefore including these genes artificially lowers X:A ratios ([@bib22], [@bib84]). When we subsequently implemented increasing thresholds of expression ranging from FPKM 0.25 to 1, X:A ratios increased in both non-gonadal and gonadal somatic cells ([Figure 2](#fig2){ref-type="fig"}A). Hereafter, we implement an FPKM of ≥1, which, based on other studies ([@bib22], [@bib50], [@bib84]), is appropriate for assaying X upregulation (see [Table S2](#mmc1){ref-type="supplementary-material"} for numbers of genes exhibiting FPKM ≥1 for each sample).

While our data supported Ohno\'s prediction that expression from the single active X chromosome is upregulated in male and female somatic tissues ([@bib61]), two points warranted attention. Firstly, contrary to expectations, confidence intervals for X:A ratios in many of our somatic samples did not cross 1 when an FPKM of ≥1 was used ([Figure 2](#fig2){ref-type="fig"}A). Upregulation affects a subset of X chromosome genes with dosage-sensitive housekeeping functions ([@bib5]). Inclusion of expressed but non-dosage-compensated X genes dilutes X:A ratios to less than 1 ([@bib62]). We therefore refined our approach, employing a strategy ([@bib65]) in which autosomal and X chromosome genes with housekeeping functions were identified by virtue of being ubiquitously expressed, i.e., exhibiting an FPKM ≥1, throughout our entire RNA-seq sample dataset. To identify this gene set, we added samples in a stepwise manner, on each occasion retaining only genes that were expressed in all conditions. As expected with this approach, addition of successive samples initially resulted in a drop in the number of genes. However, the number subsequently stabilized at 5,656 autosomal and 155 X chromosomal genes ([Figure 2](#fig2){ref-type="fig"}B; [Table S3](#mmc2){ref-type="supplementary-material"}). This ubiquitous gene set represented a sizable proportion of all expressed genes (FPKM ≥1), for example, 49.7% of autosomal and 41.2% of X-linked genes in E14.5 male liver. The number of ubiquitous genes did not change when liver, which expresses a lower number of genes compared with other tissues ([@bib65]), was excluded. Gene ontology term enrichment analysis provided strong evidence that these genes had essential housekeeping roles, for example, in the cell cycle, RNA processing, and protein localization ([Figure 2](#fig2){ref-type="fig"}C). When we repeated our analysis focusing on these ubiquitous genes, X:A ratio confidence intervals in somatic tissues crossed 1 ([Figure 2](#fig2){ref-type="fig"}D). Our approach therefore successfully enriched for X genes that are subject to upregulation.

A second consideration was that the X chromosome is over-represented in genes expressed in reproductive tissues, including gonadal somatic cells and germ cells ([@bib22], [@bib45], [@bib56], [@bib57], [@bib81]). Such genes have tissue-biased functions, and are therefore less likely to require dosage compensation. The inclusion of such highly expressed genes can skew X:A ratios to higher levels ([@bib22]). Indeed, we noted that X:A ratios were higher in some of our gonadal somatic populations than in non-gonadal somatic ones ([Figures 2](#fig2){ref-type="fig"}A and 2D). To investigate this difference further, we conducted a pairwise analysis of gene expression ratios comparing E14.5 XY male gonadal somatic cells to E14.5 XY male liver ([Figure 2](#fig2){ref-type="fig"}E). There was a significant difference in the distribution of expression from the X chromosome compared with the autosomes, and a greater proportion of highly expressed genes on the X chromosome were expressed in gonadal somatic cells (Kolmogorov-Smirnov test: p = 0.0004; [Figure 2](#fig2){ref-type="fig"}E). We controlled for this effect by imposing an upper FPKM threshold set to exclude the top centile of gene expression ([Figure 2](#fig2){ref-type="fig"}F; see [STAR Methods](#sec4){ref-type="sec"} for details). A total of 4,188 autosomal and 102 X-linked loci remained from the original ubiquitous gene set upon imposing this threshold ([Table S4](#mmc3){ref-type="supplementary-material"}). As expected, when we included this threshold, X:A ratios in gonadal somatic cell populations fell, now resembling those seen in non-gonadal somatic populations ([Figure 2](#fig2){ref-type="fig"}G). In light of these findings, we decided to analyze X dosage compensation patterns during germline development both in the presence and absence of an upper FPKM threshold. Finally, we applied our criteria to existing RNA-seq datasets from embryonic stem cells (ESCs) and epiblast-like cells ([@bib36], [@bib51], [@bib78]). We observed X:A ratios crossing 1 in male ESCs and epiblast-like cells, and crossing 2 in female ESCs ([Figure S3](#mmc1){ref-type="supplementary-material"}).

XX Female Germ Cells Exhibit Excess X Chromosome Dosage During Reprogramming {#sec2.3}
----------------------------------------------------------------------------

Next, we analyzed X dosage compensation patterns during and after reprogramming in the XX female germline. Previous work has shown that one of the two X chromosomes is already inactive in the epiblast prior to PGC specification ([@bib37], [@bib54], [@bib71]), and subsequently reactivates during germline reprogramming ([@bib14], [@bib21], [@bib71]). However, the behavior of the active X chromosome during this period has not been examined.

X:A ratios approximated 1 in epiblast cells at E6.5, whether or not an upper FPKM threshold was used ([Figures 3](#fig3){ref-type="fig"}A and 3B). Given that, in these cells, one of the two X chromosomes is silenced, this finding shows that the active X chromosome is already upregulated prior to PGC specification (see next section for confirmation). X dosage compensation was thereafter retained during germ cell migration at E9.5 ([Figures 3](#fig3){ref-type="fig"}A and 3B). Interestingly, however, from E11.5, X:A ratios increased, exceeding 1, resulting in a state of X dosage excess ([Figures 3](#fig3){ref-type="fig"}A and 3B). The relative overexpression of X genes persisted for 3 days until E14.5, i.e., after gonadal colonization and entry into meiosis ([Figures 3](#fig3){ref-type="fig"}A and 3B). This period is noteworthy since it corresponds to the time during which genes on the inactive X chromosome gradually reactivate ([@bib14], [@bib21], [@bib71]). We reappraised the behavior of the inactive X chromosome from E6.5 to E14.5 using *Xist* RNA fluorescence in situ hybridization (FISH) ([Figure S4](#mmc1){ref-type="supplementary-material"}), and found that the major loss of *Xist* clouds occurred between E9.5 and E11.5, precisely coincident with the shift to X dosage excess as determined by X:A ratio calculations ([Figure S4](#mmc1){ref-type="supplementary-material"}). Subsequently, X dosage compensation was reinstated, with X:A ratios returning to 1 at E15.5 and remaining so thereafter ([Figures 3](#fig3){ref-type="fig"}A and 3B). Thus, XX female germ cells show X dosage compensation states that are dynamic and that differ from the soma.

XO Female Germ Cells Exhibit X Dosage Decompensation Following Reprogramming {#sec2.4}
----------------------------------------------------------------------------

Our findings demonstrated that during germline reprogramming in XX female germ cells, expression of X genes undergoes dynamic changes relative to those of the autosomes, resulting in a period of excess X chromosome dosage. However, we could not decipher the relative contribution of the two X chromosomes to this unusual X dosage compensation state. To better understand this phenomenon, we repeated our analysis using germ cells from Turner syndrome female (XO) mice, which carry one rather than two X chromosomes ([Figures 3](#fig3){ref-type="fig"}C and 3D). XO mice are viable ([@bib10], [@bib11]), and therefore presumably achieve X dosage compensation through upregulation of their single active X chromosome. By assaying the behavior of this single active X chromosome in isolation, the cause of the X dosage excess observed in XX females can subsequently be deduced. We focused on four time points that in XX females represented states of initial X dosage compensation (E9.5), X dosage excess (E14.5), and reinstatement of X dosage balance (E15.5 and E18.5; [Figures 3](#fig3){ref-type="fig"}A and 3B). XO females are subfertile, but the timing of germ cell loss in these mice initiates later, at E19.5 ([@bib8], [@bib9]). Thus, our data were not confounded by germ cell elimination.

As observed in XX germ cells ([Figures 3](#fig3){ref-type="fig"}A and 3B), X:A ratios in XO germ cells at E9.5 approximated 1, confirming that XO PGCs achieve dosage compensation through upregulation of the single active X chromosome ([Figures 3](#fig3){ref-type="fig"}C and 3D). Notably, however, at E14.5, when X dosage excess was observed in XX germ cells ([Figures 3](#fig3){ref-type="fig"}A and 3B), XO germ cells retained X dosage balance ([Figures 3](#fig3){ref-type="fig"}C and 3D). A pairwise comparison revealed that the distribution of X chromosome expression was significantly different between XO and XX females at this age (Wilcoxon test, p = 8 × 10^−4^). Thus, in the female germline, upregulation of the active X chromosome is maintained at E14.5. By deduction, the state of X dosage excess in XX females at E14.5 ([Figures 3](#fig3){ref-type="fig"}A and 3B) results from the additive effects of persistent upregulation of the active X chromosome, and reactivation of the previously inactive X chromosome.

Interestingly, dosage compensation patterns in XO female germ cells changed markedly between E14.5 and E15.5. At E15.5, when XX germ cells regained X:A balance, XO germ cells became X dosage decompensated, i.e., the X:A ratio fell below 1 ([Figures 3](#fig3){ref-type="fig"}C and 3D). Thus, upregulation of the active X chromosome is lost during a 24 hr period in early meiosis. Subsequently, at E18.5, X:A ratios decreased further ([Figures 3](#fig3){ref-type="fig"}C and 3D). At this stage, XO germ cells have entered pachynema, when meiotic silencing begins to inactivate genes on the single unsynapsed X chromosome ([@bib3], [@bib76]). Meiotic silencing affects only 50% of XO oocytes and occurs in an inefficient manner ([@bib15], [@bib16]), potentially explaining why X:A ratios did not decrease more dramatically. We conclude that germline reprogramming in females is associated not only with reactivation of the inactive X chromosome but also with loss of upregulation of the active X chromosome, and that the completion of these events by E15.5 permits reinstatement of X dosage balance in E15.5 XX female germ cells. In addition, XX and XO females exhibit markedly different dosage compensation patterns.

XY Male Germ Cells Exhibit X Dosage Decompensation Following Reprogramming {#sec2.5}
--------------------------------------------------------------------------

Our findings showed that in the female germline, upregulation of the active X chromosome is lost following reprogramming, restoring X:A balance in XX females but causing X dosage decompensation in XO females. XY males, like XO females, have a single X chromosome. We therefore asked whether X dosage decompensation was also observed in the male germline. To address this, we tracked dosage compensation patterns throughout male germ cell development at equivalent time points to those analyzed in XX females.

As noted in XX and XO females, XY epiblast cells exhibited X dosage compensation at E6.5, and X:A ratios subsequently remained at 1 from E9.5 and E14.5 ([Figures 4](#fig4){ref-type="fig"}A and 4B). However, at later time points, X:A ratios in XY male germ cells fell, with upper confidence intervals no longer crossing 1. This phenomenon was observed from E15.5 when an upper FPKM threshold was imposed and from E18.5 when no upper threshold was imposed. In both scenarios, the X dosage decompensated state persisted postnatally in spermatogonia and even in leptotene/zygotene spermatocytes. At E15.5, the distribution of X chromosome expression differed significantly between XY males and XO females (Wilcoxon test, p = 0.0041), suggesting that the extent of decompensation in XY male germ cells was not as pronounced as in XO females. However, at E15.5, male germ cells are in mitosis, while female germ cells are in leptonema/zygonema. When we compared stage-matched XY male (P11) and XO female (E15.5) leptotene/zygotene cells, the X chromosome expression distributions did not differ (Wilcoxon test, p = 0.2362). We conclude that XY males exhibit X dosage decompensation after reprogramming, and that XO females exhibit a "sex-reversed" X dosage compensation pattern, i.e., one that is reminiscent of XY males rather than XX females.

XX Male Germ Cells Exhibit Excess X Chromosome Dosage During Reprogramming {#sec2.6}
--------------------------------------------------------------------------

Our analysis demonstrated that X dosage compensation patterns in XO females resemble those in XY males. We next asked the converse question, namely whether dosage compensation patterns in XX males are similar to those in XX females. We calculated X:A ratios in germ cells derived from Klinefelter syndrome variant (XX) males. These mice have two X chromosomes, and thus undergo X chromosome inactivation, but they are male due to presence of a sex reversing *Sry* transgene ([@bib52]). XX males exhibited dosage balance at E9.5, E11.5 and E12.5 ([Figures 4](#fig4){ref-type="fig"}C and 4D). However, as observed in XX females ([Figures 3](#fig3){ref-type="fig"}A and 3B), at E14.5 X:A ratios in XX males exceeded 1 ([Figures 4](#fig4){ref-type="fig"}C and 4D), and the distribution of X chromosome expression at this stage differed significantly from that in XY males (Wilcoxon test: p = 9 × 10^−4^). Germ cell loss is first evident in Klinefelter male mice from E15.5 ([@bib40]); we therefore avoided drawing conclusions about X:A ratios at this stage and after. Our findings show that, like XX females, XX males exhibit excess X chromosome dosage during reprogramming.

Dosage Decompensation in XY Male Germ Cells is not Corrected by Expression of Autosomal Retrogenes {#sec2.7}
--------------------------------------------------------------------------------------------------

A number of X genes, including some within our dataset, e.g., *Pgk1*, *Pdha1*, have duplicate copies known as retrogenes. These arise by reverse transcription of X-derived RNAs and subsequent integration at autosomal sites, and thus differ from their parental copies in being intronless ([@bib44], [@bib46], [@bib79]). Retrogenes show testis-biased expression, and some encode proteins with similar functions to their X-linked progenitors ([@bib6], [@bib19], [@bib27], [@bib66], [@bib80]). We wondered if X-derived retrogenes were expressed after germline reprogramming and, if so, whether their expression could compensate for the drop in X chromosome output that we observed in XY males during this period. Using the criteria that they should be intronless, putatively protein coding, autosomally encoded, and share \>80% nucleotide identity with their X-parental copies, we identified retrogenes for 14 of our 155 ubiquitous X genes ([Figure S5](#mmc1){ref-type="supplementary-material"}A). These retrogenes were expressed at very low levels relative to their X counterparts from E6.5--P11 ([Figure S5](#mmc1){ref-type="supplementary-material"}A). This finding was consistent with previous work showing that X-derived retrogenes initiate expression later, during, or after pachynema ([@bib44], [@bib46], [@bib79]). The X dosage decompensated state in XY male germ cells was not altered when we combined retrogene-derived RNA-seq FPKMs with those from their parental X-encoded progenitors at each stage of germ cell ([Figure S5](#mmc1){ref-type="supplementary-material"}B). We conclude that retrogenes do not compensate for the decrease in expression of their X-linked progenitors.

Conserved Dosage Compensation Patterns During Human Germline Development {#sec2.8}
------------------------------------------------------------------------

We next turned our attention to X chromosome activity during human germline reprogramming. We analyzed existing RNA-seq datasets that comprised human gonadal somatic cells and XY ESCs, as well as germ cells purified using FACS for c-KIT alone ([@bib32]) or both c-KIT and TNAP ([@bib72]). The data encompassed a broad timeline of human PGC development including early germ cells, when germline reprogramming occurs (weeks 5.5, 7, and 9) and later germ cells, when sexually dimorphic development takes place ([Figure S1](#mmc1){ref-type="supplementary-material"}). Where available, biological replicates were pooled as indicated ([@bib72]). We used this entire sample set to generate a set of ubiquitously expressed (FPKM ≥1) genes, in a manner similar to our approach in mice. We identified 8,226 autosomal and 259 X-linked ubiquitously expressed genes ([Table S5](#mmc4){ref-type="supplementary-material"}), which fell to 7,719 autosomal and 236 X-linked genes when an upper FPKM threshold was imposed ([Table S6](#mmc5){ref-type="supplementary-material"}). We observed X:A ratios of 1 for these genes in XY ESCs and gonadal somatic cells, in the presence or absence of an upper FPKM threshold ([Figure 5](#fig5){ref-type="fig"}A), indicating that X upregulation occurs in these populations. Notably, however, germ cells exhibited dosage compensation patterns that differed from the soma, and were reminiscent of those seen in mouse germ cells. During germline reprogramming (weeks 7--9), when reactivation of the inactive X chromosome takes place ([@bib72]), XX female samples derived from [@bib72] exhibited X dosage excess, both in the presence or absence of an upper FPKM threshold ([Figures 5](#fig5){ref-type="fig"}B and 5C). This phenomenon was not observed in males ([Figures 5](#fig5){ref-type="fig"}D and 5E). Furthermore, after germline reprogramming, while X:A ratios in females returned to 1 ([Figures 5](#fig5){ref-type="fig"}B and 5C), those in males fell below 1, resulting in an X dosage decompensated state ([Figures 5](#fig5){ref-type="fig"}D and 5E). We conclude that differences in X dosage compensation states exhibited between somatic and germ cells, and between females and males, are conserved in mice and humans.

Discussion {#sec3}
==========

Here, we have tracked X dosage compensation patterns in mouse and human germ cells from their inception through to their later development. We uncover unusual X dosage compensation states that differ between the germline and the soma and between males and females, and that are conserved in humans ([Figure 6](#fig6){ref-type="fig"}).

During their specification and migration, female and male germ cells exhibit X:A ratios of 1, showing that upregulation of the active X chromosome is present in both sexes during early germline development ([Figures 6](#fig6){ref-type="fig"}A--6D). Subsequently, however, X dosage compensation patterns become sexually dimorphic. During reprogramming in XX female mice, X:A ratios exceed 1, generating a state of X dosage excess that persists for 3 days from E12.5 to E14.5 ([Figure 6](#fig6){ref-type="fig"}A). We propose that the excess X chromosome output arises from reactivation of the inactive X chromosome, combined with ongoing upregulation of the active X chromosome. While supported by analysis of XO females, it is also possible that this excess X dosage in XX females results from a modest increase in expression from both X chromosomes. This alternative hypothesis could be tested in future by allele-specific RNA-seq. Upregulation of the active X chromosome is subsequently reversed between E14.5 and E15.5. In XX females, this corrects the hyperactive X state ([Figure 6](#fig6){ref-type="fig"}A), but in XO females it leads to X dosage decompensation ([Figure 6](#fig6){ref-type="fig"}B). The decompensated state in XO females is independent of meiotic silencing, which occurs later, at E16.5--E18.5 ([@bib16]). Our findings, together with previous work ([@bib29]), show that X upregulation no longer occurs in XO and XX females after reprogramming.

As observed in female germ cells, output from the active X chromosome in XY male germ cells falls following reprogramming, resulting in X:A ratios below 1 ([Figure 6](#fig6){ref-type="fig"}C). At leptonema/zygonema, the extent of decompensation in XY males is similar to that of XO females. Nevertheless, reversal of X upregulation in XY males clearly occurs over a more protracted period (i.e., days) than in XO females (hours). Sexual dimorphisms are regulated by X dosage or X imprinting effects, or by the presence or absence of the Y chromosome ([@bib2]). Given that XO females and XY males both have a single X chromosome of maternal origin, differences between these models must be due to the Y chromosome. The Y chromosome could influence X dosage compensation states as a result of *Sry* determining male gonad development (i.e., phenotypic sex), or/and the continued effects of other Y-encoded genes that could modulate X dosage compensation states. It is already well established that the X chromosome is silenced during pachynema by the process of meiotic sex chromosome inactivation (MSCI) ([@bib41], [@bib42], [@bib75], [@bib83]), but its activity before this time has not been thoroughly investigated. Our current findings show that expression from the X chromosome in fact undergoes a stepwise decrease during male germline development: prior to reprogramming, the X chromosome is fully upregulated, at leptonema/zygonema upregulation is lost, and subsequently, during pachynema, it is fully silenced by MSCI.

Finally, our studies are informative with respect to understanding the etiology of infertility in sex chromosome aneuploidies. XO females exhibit X chromosome decompensation reminiscent of that seen in wild-type males, while XX males exhibit X dosage excess like that in wild-type females. We suggest that this sex-reversed X dosage compensation pattern could contribute to the infertility phenotypes. For example, while it is accepted that infertility in XX males is due to reactivation of the inactive X chromosome ([@bib35], [@bib55]), one model attributes this specifically to a double dose of genes showing spermatogonial-specific expression ([@bib20]). Our data present an additional possibility, in which germ cell loss in XX males results from a mismatch between germline sex and X dosage compensation state. Previous work advocates a predominant role for dosage-sensitive X genes in sex chromosome aneuploid phenotypes ([@bib62]). In either scenario, preventing X chromosome reactivation or promoting loss of the excess X chromosome may prove of therapeutic benefit in Klinefelter syndrome infertility.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

Reagent or ResourceSourceIdentifier**Critical Commercial Assays**Ultralow input RNA-Seq Kit (SMARTER)ClontechCat No \#634935**Deposited Data**Our raw and analyzed RNA-seq datasetThis paperEuropean Nucleotide Archive (EMBL-EBI) [E-MTAB-4616](array-express:E-MTAB-4616){#intref8060}**Experimental Models: Organisms/Strains**Mouse: Oct-4 EGFPWolf Reik/Azim Surani, Cambridge, UK-na-Mouse: ROSA26-\
540 Tomato-EGFP strain (ROSAmT/mG)The Jackson LaboratoryGt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)LuoMouse: XY- +Sry (B6)Francis Crick Institute-na-Mouse: X^Y^O maleFrancis Crick Institute, [@bib7]-na**Sequence-Based Reagents**Xist RNA FISH probes[@bib53]fosmid probe: W11-2363-H9**Software and Algorithms**TopHat v2.0.13Genome Biology 2013 14:R36<http://www.ccb.jhu.edu/software/tophat/index.shtml>Cufflinks v2.2.1[@bib73]<http://cole-trapnell-lab.github.io/cufflinks/>R v.3.2.0R Core Team (2016)<https://www.R-project.org/>cummeRbund v2.7.2 (R package)L. Goff, C. Trapnell, D. Kelley<http://compbio.mit.edu/cummeRbund/>pairwiseCI (R package)Frank Schaarschmidt \[aut, cre\], Daniel Gerhard \[aut\]<https://cran.r-project.org/>RtsneJesse Krijthe \[aut, cre\], Laurens van der Maaten \[cph\] (Author of original C++ code)<https://cran.r-project.org/>**Other**Smart-Seq2 protocol[@bib64]NAMouse genome and annotation<ftp://igenome:G3nom3s4u@ussd-ftp.illumina.com/Mus_musculus/UCSC/mm10/Mus_musculus_UCSC_mm10.tar.gz>mm10Publically available data ES-cell RNA-seq datasets accessedEuropean Nucleotide Archive (EMBL-EBI)SRR1448385, SRR1448386, SRR1448387, SRR1448388, SRR4241903, SRR4241904, SRR4241905, SRR4241906, SRR4241907, SRR4241908

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for reagents may be directed to, and will be fulfilled by the Lead Contact, Dr. James Turner, <james.turner@crick.ac.uk>.

Experimental Model Subject Details {#sec4.3}
----------------------------------

### Mice {#sec4.3.1}

Oct4-EGFP mice were obtained from the Reik lab (Babraham, Cambridge, UK) and maintained on a B6 background. The reporter strain was used to isolate fluorescently marked germ cells through FACs. Homozygous XY^−^ +*Sry* (C57B6) Oct4-EGFP males were crossed with XX Oct4-EGFP females to yield XX female, XY male and XX male embryos used in the study.

XO embryos were generated by crossing an MF1 X^Y^O male ([@bib7]) to an XX Oct4-EGFP female. Timed matings were undertaken, and noon on the date of the vaginal plug was taken to be E0.5. Embryos were subsequently harvested on the stipulated day.

Leptotene/zygotene stage male germ cells were isolated at postnatal Day 11, by crossing a Stra8-*cre* line with ROSA26-Tomato-EGFP strain (ROSA^mT/mG^ strain; Mouse strain \#007676 from The Jackson Laboratory), which enabled the timely isolation of these germ cells during the first-wave of male meiosis through FACS.

Samples were sexed as female (XX or XO) or male (XY or XX *Sry* transgenic) by a combination of gonadal inspection, conventional PCR genotyping and the presence of Y chromosome-derived transcripts from RNA-Seq data. Each condition comprised of at least two replicates. All animal procedures were in accordance with the United Kingdom Animal Scientific Procedures Act 1986 and were subject to local ethical review.

Method Details {#sec4.4}
--------------

### Isolation of Cells for RNA-Seq Analysis {#sec4.4.1}

Cell populations derived and purified from a single embryo at any stated age constituted a biological replicate to be used in subsequent steps. Germ cell and somatic populations were isolated at different stages, ranging from E9.5, E11.5, E12.5, E14.5, E15.5, E16.5, E18.5, P2, and P11. RNA was purified from individual E6.5 epiblasts.

### Fluorescence-Activated Cell Sorting (FACS) {#sec4.4.2}

Germ cells (GFP-positive) and associated somatic cells (GFP-negative) were isolated separately from individual embryos using FACs sorting on the MoFLo XDP or FACS Aria platforms. Live cells, i.e. only those staining negative for propidium iodide, were collected, and typically purity checking on the GFP negative populations was \>99%.

### Isolation of RNA and Construction of cDNA Libraries {#sec4.4.3}

RNA was isolated from FACs sorted purified cell populations using the Ambion RNA isolation kit (Ambion \#AM1931). Eluted RNA was used to obtain double-stranded-cDNA using the Clontech (SMARTER) Ultralow input RNA-Seq Kit according to the manufacturer\'s protocol, or the Smart-Seq2 protocol ([@bib64]). cDNA was normalized to 10 ng in low-TE buffer and was sheared using Covaris S-series, and was cleaned up with Zymo DNA conc-5 and eluted in 12 ul low-TE buffer. Libraries of ∼300 bp were generated using Nugen Ovation Ultralow DR (part No. 0330) with 15 PCR cycles. Paired-end sequencing of 50 cycles was performed on the Illumina HiSeq2500 sequencer in house.

### RNA FISH {#sec4.4.4}

Sample embryos were collected and fixed in 4% paraformaldehyde overnight at 4°C. Samples were then placed in 30% sucrose solution overnight. These were then placed in Optimal Cutting Temperature (OCT) compound and transferred to appropriate molds, quick-frozen and then stored at −80°C until the time of cryosectioning. 5 μm cryosections were collected and placed on coverglasses, and subsequently processed with *Xist* RNA FISH probes using an established protocol ([@bib53]). Germ cells at E9.5, E11.5 and E14.5 were identified by the detection of expression of the *Oct4*-EGFP reporter transgene and nuclear morphology as visualised with DAPI DNA staining.

Quantification, Statistical Analysis and Additional Resources {#sec4.5}
-------------------------------------------------------------

### Bioinformatic Analyses {#sec4.5.1}

Reads were aligned to the mouse genome (mm10) using Tophat2 v2.0.13. Transcript abundances were calculated using Cufflinks2 and Cuffdiff ([@bib47], [@bib73], [@bib74]). At a minimum we had included two biological replicates for each condition that was analyzed (see [Table S1](#mmc1){ref-type="supplementary-material"}). As recommended, annotated rRNA, mitochondrial transcripts and other very highly abundant transcripts were ignored from the analysis. Calculated transcript abundances in FPKM (Fragments per Kilobase per Million reads) were subsequently used in further analyses in R. Data visualization, hierarchical clustering and MDS were performed using the cummeRbund package. X:A ratios with 95% confidence intervals were calculated using the pairwiseCI package in R using \'Median.ratio\' with 1,000,000 bootstrap replications.

We imposed an upper FPKM threshold that corresponded to the lowest 99^th^ centile FPKM value of expression across conditions. ES Cell RNA seq datasets were accessed from the European Nucleotide Archive database.

Relevant samples from Study accession numbers PRJNA342888 and PRJNA253304 were accessed (Run accession numbers used are as stated in [Figure S3](#mmc1){ref-type="supplementary-material"}) ([@bib51], [@bib78]). These samples were aligned using Hisat2 --v2.0.5 to the mouse genome (mm10). Expression values (FPKM) and X:A ratios were calculated as stated.

### Retrogene Analysis {#sec4.5.2}

Annotated retrogenes were retrieved from the UCSC Genome Bioinformatics database from the mm10 mouse genome using Table Browser function and 18,456 records were obtained. X-linked genes from our ubiquitously expressed set of genes ([Table S2](#mmc1){ref-type="supplementary-material"}) were cross-referred to this dataset. 14 out of 155 ubiquitous X-genes had autosomal retrogene counterparts which were intronless, putatively protein-coding and shared \>80% nucleotide identity with their X-parental copies.

Data and Software Availability {#sec4.6}
------------------------------

### Software {#sec4.6.1}

All software programs used in this study were from publicly available resources. Please refer to [Key Resources Table](#sec4.1){ref-type="sec"} for more details.

### Data Resources {#sec4.6.2}

The dataset has been submitted via ArrayExpress to the European Nucleotide Archive (EMBL-EBI) and is publicly available under accession number ArrayExpress: [E-MTAB-4616](array-express:E-MTAB-4616){#intref7060}
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![Transcriptome Profiling of Mouse Germ Cells\
(A) Unsupervised hierarchical clustering of all dataset samples. The dendrogram shown is based on Jensen-Shannon distances between conditions. Dark orange, epiblast and early germ cells; dark blue, late germ cells; green, somatic cells; gray, E12.5 XX male germ cells.\
(B) MDS plot of gene expression in all replicates within the dataset.\
(C) Time course of relative expression (FPKM) for pluripotency genes in XY males and XX females.\
(D) Time course of relative expression (FPKM) for meiosis genes in XY males and XX females.](gr1){#fig1}

![Analysis of X:A Ratios in Somatic Cells\
(A) Bootstrapped X:A ratios from E14.5 liver and tail and gonadal somatic cell populations (E9.5--P11; E9.5 refers to caudal embryo somatic cells) using different lower FPKM thresholds, and focusing on all genes (i.e., "non-ubiquitous genes").\
(B) Definition of a ubiquitous gene set by addition of sequential samples of germ cells and somatic cells. The number of genes expressed in "all samples" is predictably high when the number of samples included is low and decreases as more samples are added before plateauing at a stable gene set.\
(C) Gene ontology (GO) enrichment analysis, defined using Database for Annotation, Visualization and Integrated Discovery (DAVID), of ubiquitously expressed genes (5,656 on the autosomes and 155 on the X chromosome). Benjamini-Hochberg-corrected p values were plotted against the top ten "biological processes" GO terms.\
(D) X:A ratios for the same samples as in (A), but considering only ubiquitous genes.\
(E) Density plot of log~2~ FPKM ratios of expression in E14.5 XY male gonadal somatic cells and E14.5 XY male liver for the X chromosome versus the autosomes.\
(F) Density plot of log~2~ FPKM ratios of expression in E14.5 XY male gonadal somatic cells and E14.5 XY male liver for the X chromosome versus the autosomes, after imposition of an upper FPKM expression threshold.\
(G) X:A ratios for the same samples as in (A) and (D) considering only ubiquitous genes together with an upper FPKM threshold.](gr2){#fig2}

![X:A Ratios in XX and XO Female Mouse Germ Cells\
(A) X:A ratios of ubiquitously expressed genes in XX females using an FPKM ≥1 and an upper expression threshold.\
(B) X:A ratios of ubiquitously expressed genes in XX females using an FPKM ≥1 and no upper expression threshold.\
(C) X:A ratios of ubiquitously expressed genes in XO females using an FPKM ≥1 and an upper expression threshold.\
(D) X:A ratios of ubiquitously expressed genes in XO females using an FPKM ≥1 and no upper expression threshold.\
Dark orange, epiblast and early germ cells; dark blue, late germ cells.](gr3){#fig3}

![X:A Ratios in XY and XX *Sry* Male Mouse Germ Cells\
(A) X:A ratios of ubiquitously expressed genes in XY males using an FPKM ≥1 and an upper expression threshold.\
(B) X:A ratios of ubiquitously expressed genes in XY males using an FPKM ≥1 and no upper expression threshold.\
(C) X:A ratios of ubiquitously expressed genes in XX *Sry* males using an FPKM ≥1 and an upper expression threshold.\
(D) X:A ratios of ubiquitously expressed genes in XX *Sry* males using an FPKM ≥1 and no upper expression threshold.\
Dark orange, epiblast and early germ cells; dark blue, late germ cells.](gr4){#fig4}

![X:A Ratios in Human XY ESCs, Gonadal Somatic Cells, and Germ Cells\
(A) X:A ratios of ubiquitously expressed genes in XY ESCs, and week 7 male gonadal somatic cells and female gonadal somatic cells using an FPKM ≥1 and the presence or absence of an upper FPKM threshold.\
(B) X:A ratios of ubiquitously expressed genes in XX female germ cells using an FPKM ≥1 and an upper expression threshold. Data from [@bib72] are shown with closed circles; data from [@bib32] are shown with open circles.\
(C) X:A ratios of ubiquitously expressed genes in XX female germ cells using an FPKM ≥1 and no upper expression threshold.\
(D) X:A ratios of ubiquitously expressed genes in XY male germ cells using an FPKM ≥1 and an upper expression threshold.\
(E) X:A ratios of ubiquitously expressed genes in XY male germ cells using an FPKM ≥1 and no upper expression threshold.\
Dark orange, early germ cells; dark blue, late germ cells.](gr5){#fig5}

![A Model for X Dosage Compensation Patterns\
A model for X dosage compensation patterns in the XX Female (A), XO female (B), XY male (C), and XX male (D) mammalian germline. Prior to reprogramming, XX female and XX male germ cells have one upregulated X chromosome (Xa, orange) and one inactive X chromosome (Xi, gray), while XY males and XO female cells have a single upregulated X chromosome (Xa, orange). In all four cases, the dosage of X genes is balanced with that of the autosomes (A, blue), i.e., the X:A ratio is 1. During reprogramming, upregulation of the active X chromosome is maintained in all four genotypes, but in XX females and XX males, the inactive X chromosome begins to reactivate (gray becomes blue). The outcome is X:A ratios greater than 1 in XX females and in XX males. Later, X upregulation is lost, reinstating X:A ratios in XX females to 1, but leaving XY males and XO females X dosage decompensated, with X:A ratios less than 1. XX males show germ cell loss from E15.5, which may be due to high X:A ratios seen.](gr6){#fig6}
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